Premium
Hydroxychloroquine treatment for Alopecia Universalis: Report of six cases
Author(s) -
Akdogan Neslihan,
ErsoyEvans Sibel
Publication year - 2021
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.13391
Subject(s) - hydroxychloroquine , medicine , alopecia universalis , refractory (planetary science) , dermatology , hair loss , surgery , covid-19 , disease , physics , astrobiology , infectious disease (medical specialty)
Abstract Recent reports indicate that hydroxychloroquine is a potential new treatment option for alopecia universalis; thus, we aimed to report on the safety and efficacy of hydroxychloroquine in 6 patients with refractory alopecia universalis that were treated with 400 mg/d continuously for ≥6 months. The treatment outcome was retrospectively evaluated using the Severity of Alopecia Tool (SALT), and at the end of 6 months, patients with a ≥50% decrease in the SALT score were considered as strong responders, a 5%‐50% decrease as intermediate responders and a <5% decrease as non‐responders. The present findings indicate that hydroxychloroquine is not an effective treatment since in 5 of the 6 patients it was discontinued at the end of 6 months due to lack of hair regrowth, whereas only a 6‐year‐old boy responded with a SALT score change of 8% after the 12th month.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom